Health As Never Before



Alphanosos is an R&D company which aim to license its products to major players of the related industries.

Alphanosos has a development program of cosmetics and food supplement and will bare the cost to propose ready to launch products with clinical proof.

The drug development process with high dose product and medical indication will be initiated under the botanical process in the US after signed partnership

Alphanosos is reinventing plant-based pathogen control, well-being and medicine through its R&D based on proprietary Artificial Intelligence (AI)
Biology unfolds the extraordinary potential of active combinations of edible botanicals in many domains: health, food, cosmetic, agriculture,…
  • Edible botanicals are cheaper to produce than chemical products.
  • They generate less side-effects and addiction.
  • Their adequate use, in an efficient and respectful way, is more environmental-friendly, viable and socially acceptable.
  • At Alphanosos we extract the actives from plant mixes using water as a "solvent". We thus speak of WECMEPs for "Water Extracts of Complex Mixes of Edible Plants". WECMEPs are our equivalent of "chemical class" for drug discovery.
    However, finding the adequate WECMEP for a pathology could generate an infinity of combinations to tests… a dead-end road?
    From more than 5 years of research, we have developed a unique deep-learning algorithm and process know-how, allowing us to design, in only a few experimental iterations, WECMEPs with efficient action on a pathology to create what we call Ediceuticals.
    Our « Smart Ediceutical » technology has allowed to release several WECMEPs containing products, including veterinary products to fight pyoderma, and a currently on-test proven-efficient WECMEP for the Covid-19. We are exploring other applications driven by market opportunit and cleint demand.
    Based on experimental measurements, Alphanosos' proprietary AI algorithms are able to rapidly discover the most effective mixes of edible botanicals to fight against microbial agents.
    This high-tech research method highlights plant synergistic activities from a library of 300-1000+ edibles to create and patent new generations of botanical active ingredients with high efficacy.



    Our approach holds similarities with multitherapy already currently used when fighting against aggressive pathogens such as AIDS and Cancer: drugs are combined to maximize efficacy.

    But our AI applied to edibles allows to take full advantage of this concept. By combining thousands of different chemicals each way below its pharmacological dose but acting in synergy, we obtain both efficacy and safety, making for the first time evidence based Massive Network Pharmacology a reality.

    • Alphanosos’ complex mixes contain massive chemical diversity extracted from edible botanicals.

    • Taken alone and separately, compounds in the mix have no significant pharmacological effect.

    • Combined by artificial intelligence into complexes mixes against targeted pathogens they litteralty induce dietary imbalance creating massive system perturbation, which is the basis of an Ediceutical.

    • The more diversity in compounds,the less the concentration of each,the less the risk of undesired effects, the more opportunities for synergistic


    Organism: Dietary Time: Generation Time: System's Robustness:
    Humans,pets,farm animals 24h "10~20" years (humans) Very High
    Microorganism acute infections Minutes 0.5-1 hour Much less than human cells
    Microorganism silent/slow infections 24h Day(s) Much less than human cells
    Malignant tumor cells hours? "Months" (to metastasis) Less than non mutated normal cells

    Alphanosos used its AI to create WECMEPs active
    against bacteria resistant to nearly all existing traditional antibiotics

    Neisseria gonorrhaeae strain WHO Z is resistant to nearly all traditional antibiotics. Alphanosos has identified several WECMEPs figting WHO Z, the best with MIC 100µg/mL

    Thanks to their high molecular diversity, there is no resistance emerging against Alphanosos' WECMEPs over time

    Alphanosos used its AI to create WECMEPs active
    against human cancer cells

    Alphanosos' WECMEPS kill cancer cells in vitro in this 72 hours experiment

    Extracts are safe for normal cells

    Alphanosos uses its rapid AI guided discovery platform to create WECMEPs preventing the development of COVID's coronavirus in vitro

    Discovery initiated mid-November 2020, results presented: mid-January 2021

    Coronavirus experiments realized by independent CRO Vibiosphen (Toulouse France)

    Alphanosos created an extract active against canine superficial pyoderma

    Peer reviewed article published in "Veterinary Dermatology"

    See Abstract

    Alphanosos created a cosmetic serum for atopic skins around one of its patented extract elaborated with AI

    Already highly apreciated by first users

    Formal clinical evaluation results will be available second quarter 2021

    Publications and communications


    Commercially available product

    The World Health Organization (WHO) Global Burden of Diseases initiative estimates more than 230 million people globally have atopic dermatitis (AD), and that skin diseases continue to be the fourth leading cause of non-fatal disability worldwide.
    • 62.8% of patients report itching at least 12 hours per day.
    • 61% of affected adults report pain
    • Sleep disturbance occurs in approximately 60% of children
    • More than 55% of adults with moderate-to-severe AD report inadequate disease control.
    A recent meta-analysis placed the rate of S. aureus carriage by AD patients at about 70 percent on lesioned skin versus 39 percent on non-lesioned skin or healthy control. skin.

    A very comprehensive and recent study published in Nature, related to microbiome and Atopic dermatitis and psoriasis defined a disbalanced profile for AD patients as compared to healthy control (Microbe-host interplay in atopic dermatitis and psoriasis - Fyhrquist N, et al. Nat Commun 2019).
    Available for licensing/distribution,
    also soon available directly from us.


    Preclinical data

    Our COSMOS certified ingredient "Synherbs 5.2-bio-cosmos" is being developped into an adult acne product.
    Alphanosos has begun to develop with its AI-guided rapid discovery technology, extracts acting against Cutibacterium acnes with botanicals suitable for use in adolescents.

    The Global Burden of disease study 2010 found than acne vulgaris is the eight most common skin disease.
  • 70% of children an teens report acne.
  • Literature shows that adult women are also affected approximately 12 to 22 percent of United States women suffer from adult acne, compared to three percent of men.
  • The anaerobic bacterium Cutibacterium acnes is believed to play an important role in the pathophysiology of the common skin disease acne vulgaris.

  • Expected commercial availibility: end 2021.
    Available for licensing/distribution.
    Alphanosos develops an extract acting on relevant microorganisms found in psoriasis dysbiosis while restoring the skin microbiome's balance.
    Psoriasis is a serious global problem with at least 100 million individuals affected worldwide.
    • Current concepts of pathogenesis indicate the contribution of genetic, immunologic and environmental factors.
    • The presence of bacteria on and in the skin was also considered in the pathogenesis of psoriasis. Microorganisms such as S. Aureus which usually resides on the skin, has also been implicated in the pathogenesis of psoriasis 
    Expected commercial availibility: end 2022.
    Available for licensing/distribution.

    Alphanosos develops an extract acting against Candida albicans. Potential candidates are already identified and product development is ongoing.
    Surveys suggest that about 75% of women develop vulvovaginal candidiasis (thrush or Yeast infection) at least once in their lifetime.
    • The 25-34 year age group has the highest prevalence (9%).
    • By 2030, the population of women with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million
    • Candida albicans remains overall the most common causative pathogen (33.8–60%), however, non-albicans Candida species are increasing
    Expected commercial availibility: end 2022.
    Available for licensing/distribution.

    You think we can do more for you in Human Dermatology ?
    Let us know!

    We, at Alphanosos, are willing to relieve additional dermatological conditions².
    This development program is just a part of what the technology we developed can bring as dermatological improvement. Now if:
  • You are a cosmetic or dermatological company,
  • You are an association member supporting patients suffering from such disease or ailment.
  • You think we could contribute to relieve those people from pain or health impairment,
  • then please just let us know, contact us!


    WHO defines self-care as “the ability of individuals, families and communities to promote health, prevent disease, maintain health, and to cope with illness and disability with or without the support of a healthcare provider”.

    The products developed with the Alphanosos technology will help the organism of family members to fight against pathogens without arming their environment and without promoting resistance of pathogens.
    Being based water extract of edible plant, the Alphanosos product will be:
  • unprecedently safe,
  • 100% natural,
  • 100% sustainable
  • At this stage we have a development program targeting the most common cause of health disorders in which the Alphanosos technology could provide some relief to people trusting our products











    Available for licensing/distribution,
    also soon available directly from us.

    Do you have interest in other Human Selfcare applications?
    Let us know!

    Besides, at Alphanosos, are also willing to relieve painful diseases.

    This development program is just a part of what the technology we developed can bring as health improvement and pathogen control in general.

    Our technology calls for being applied to pressing difficult health issues: controlling viral pandemics, solving the rise of antibiotic resistance, orphan oncology situations, et more generally any disease where traditional chemical and biotechnological approaches provide unsatisfying responses, if any. We are thinking of migraine, pain, Alzheimer’s, Lyme’s, etc.

    Now if:
  • You are a company involed in fighting a disease or faced with a technical problem involving pathogens,
  • You are an association member supporting patients suffering from such disease or ailment.
  • You are a scientist, an activist or a charity supporting new approaches in health

  • then please just let us know, contact us!


    Commercially available product

    Pyoderma literally means “pus in the skin.” Surface pyoderma is a very common condition in small animal practice. A survey of 100 small animal vets in the UK found that 7% of all dogs seen in the summer exhibited surface pyoderma.

    Most cases of pyoderma are caused by bacterial infections. The primary pathogen of dogs is Staphylococcus pseudintermedius. Most of these are superficial and secondary to a variety of other conditions, such as allergies or parasites. Pyoderma that occurs in otherwise healthy animals usually resolves completely with appropriate antibiotics.

    Bacterial resistance is an emerging conditions. The most common resistant organism in veterinary dermatology is Methicillin resistant Staphylococcus pseudointermedius MRSP. .

    Available for licensing/distribution,
    also available directly from us.


    March 9th, 2021, Press Release: Towards oral treatment against the Covid19 virus developed by a French deeptech

    Alphanosos is a French deeptech health company that has developed a product coined W17P47 that has now demonstrated its effectiveness against the COVID-19 virus in an in-vivo humanized mice model treated orally.

    These results are very important in the context of the current pandemic. They have been obtained with humanized K18-hACE2 mice contaminated with 2.5x104 PFU virus. This dose is systematically lethal in the absence of treatment. Until now, only injectable high-dose monoclonal antibodies or sera of convalescent patients had produced results in this extremely severe model. This protocol is therefore an extremely selective efficacy test.

    This is the first time that an oral curative treatment has achieved survival results in this model: 100% of mice in the control group died while 30% survived in the W17P47 treatment group. This product had already demonstrated its efficacy in a cell culture model (Vero E6) infected with Sars-CoV-2 with a level of efficacy compared to Remdesevir.

    These results are very promising because the experiment used a dose than can indeed be administered to patients orally. In addition, the safety and usage profile of the treatment is intended for the greatest number of patients.

    To continue its development and move quickly towards a clinical evaluation, Alphanosos is looking for funding and investigation centers to conduct such studies. To this end, the company submitted a "national health priority" label application to the French ANRS.

    Alphanosos is evaluating whether its therapeutic approach, both paradigm shifting and natural, perfectly adapted to the corresponding “botanical drug” legislation of the FDA in the USA, can also be accepted by the health authorities in France and the EU.

    Indeed, Alphanosos’ treatment includes a very large number of molecules. Taken individually and in low doses, they are harmless to humans and the environment because they are edible and natural. They are assembled by AI to make therapeutic potential emerge thanks to synergies that had not been documented before. In this way, this treatment increases the concept of multitherapy used against AIDS or certain cancers. Alphanosos already offers such treatments against health-threatening multidrug-resistant bacteria that are still waiting to arouse the interest of the medical and pharmaceutical communities.

    Alphanosos’ leaders Pascal Mayer, Founding President, and Jacques Chevallet, Director of Operations, hope the urgency of the COVID-19 will allow such natural and safe innovations to be taken into account quickly to complement vaccines in the anti-pathogenic therapeutic arsenal.

    February 1st, 2021, Press Release: A major breakthrough in the fight against Covid19

    Alphanosos is a French Green-Health DeepTech company, specialized in the research of new innovative treatments. The company has developed proprietary artificial intelligence to elaborate, from aqueous botanical extracts, highly effective products against viruses, bacteria or cancer cells. This innovative approach tackles the most resistant pathologies thanks to its active ingredients, capable of unbalancing and eliminating the pathogenic target without impairing the host.

    Artificial intelligence makes it possible to identify among 10^40 mixing possibilities of 1000 plants preselected for their safety, the one mix that will act against the pathogen target but not against the host organism. The target is thus subjected to massive perturbations by a large number of highly diverse molecules, each at low dosage but acting together to empirically obtain the desired effect on the target organism. This is the principle of multitherapy “raised to the power of 10”.

    This approach has already demonstrated its effectiveness with in vitro experiments on Staphylococcus aureus, which is multi-resistant to powerful antibiotics. This activity has been confirmed with in vivo tests by achieving 100% survival of treated mice versus 100% mortality of untreated mice after induced sepsis.

    Today, Alphanosos discovered an effective product against SARS-Cov2 that has achieved superior efficacy relative to the best drug candidates. Without toxic risk, affordable, easy to manufacture and supported by convincing research results, this product brings a breakthrough innovation in the fight against COVID19. This French product revives the French experimental discovery tradition that Claude Bernard embodied in his time.

    Developed from common edible plants, the non-toxic and easy-to-produce W17P4690 will enter animal testing mid-February. A clinical study is envisaged for March. The product will be available in May.

    The company Alphanosos is now looking for support to finalize its development and accelerate its contribution to controlling the COVID19 crisis.

    January/September 2020: preprint and peer reviewed publication on the safety and mode of action of Ediceuticals and WECMEPs are published

    The peer reviewed paper entitled "Modelling bioactivities of combinations of whole extracts of edibles with a simplified theoretical framework reveals the statistical role of molecular diversity and system complexity in their mode of action and their nearly certain safety" has been published as Mayer P, PlosOne 2020 Sep 28;15(9):e0239841. The preprint had been made available on bioRxiv.

    This work explains how the mode of action of Alphanosos' WECMEPs (Water Extract of Complex Mix of Edible Plants) can be summarized as massively parallel system perturbation towards which normal eukaryotic cells are far more robust than impaired (cancer/infected) cells and microorganisms.

    January 2019: Alphanosos starts the commercialization of Effiskin®, the first veterinary hygiene product based around an active elaborated using Artificial Intelligence

    Alphanosos is proud to announce the availability of its first non-registered commercial product resulting from its AI based discovery efforts: Effiskin® lotion, a purifying hygiene product adapted to pyoderma prone skins and developed based on human dermo-cosmetic standards for demanding vets and dog owners. It is formulated around Synherbs®16P926, an EffiSkin® exclusivity. Additional veterinary hygiene products will be launched throughout 2019.

    Synherbs®16P926 is a patent pending WECMEP (Water Extract of Complex Mix of Edible Plants) which has been elaborated scientifically using Alphanosos’ genuine Artificial Intelligence based discovery methodologies. It allowed for the first time to discover purifying synergies among many billion edible plant mixes possibilities. This 100% natural active is obtained using processes without chemical solvents and is extremely environment-friendly. Associated to a natural thickener, Synherbs®16P926 creates a favorable environment on the dog’s skin so that persistent irritation sources can be resolved efficiently and naturally. Effiskin® also contains natural restructuring and moisturizing agents to improve skin hydration (superficial epidermal layers).

    Effiskin®’s innocuity has been evaluated under veterinary control and an efficacy study is being initiated with a French veterinary school. User’s testimonies updates are available on our product page and brochure.

    This product starts being available through veterinaries, pharmacies and additional pet professionals in different countries, starting with France and Switzerland. Contact us for knowing your nearest distributor at Additional distribution agreements are under discussion and some countries are still available for exclusive distribution.

    March 2018 (published 05/2019): Alphanosos sells one of its cosmetic product development project to Syha-Paris

    One of Alphanosos’ cosmetic product development project (formulations and know-how) has been sold to French startup Syha-Paris ( ). Syha-Paris will incorporate Alphanosos’ patent pending active Synherbs® 4.5-bio-cosmos in its initial product lines.

    June 2017: Alphanosos has been granted the “COSMOS Certified Ingredients” label for 2 cosmetic ingredients based on discoveries obtained with its artificial intelligence based discovery tools

    Among Alphanosos’ synergistic plant mixes discoveries included in its recent patent application (see November 2016 news), several were identified to be of high interest for cosmetic applications. For two of them, we entered scale-up developments compatible with the COSMOS Certified Ingredients requirements.

    After careful review of our dossier and an inspection visit in June, Ecocert GREENLIFE SAS (France) issued a certificate of compliance on our two ingredients and manufacturing process, which together deserve the “COSMOS Certified Ingredients V2“ label.

    These plant mixes can now be incorporated in cosmetics targeting the “COSMOS Organic” certification. Alphanosos has already licensed one of these ingredients to a European company on restricted geographic territories and products.

    Alphanosos is now leading the development of a cosmetic line incorporating one of these ingredients that is to comply with “Cosmos Organic” requirements.

    November 2016: Alphanosos files a patent application on a large family of anti-staphylococci plant extracts obtained with its artificial intelligence based discovery tools

    Alphanosos’ patent application covers complex and synergistic mixes of plant extracts with anti-biofilm and antibiotic activities against staphylococci, including MRSA. The patent exemplifies the activity of more than 600 of such mixes and includes animal model results for activity against systemic infection.

    The active plant mixes could be identified out of an astronomical number of possible plant combinations by using Alphanosos’ proprietary and genuine artificial intelligence powered screening data analysis algorithms and software.

    The synergistic plant mixes’ activity is highly specific of staphylococci and insensitive to the antibiotic resistance profiles of the strains. The plants composing the mixes have a history of safe human consumption. These properties open a large window of fast-to-market opportunities for therapeutic indications in humans and animals where existing antibiotics cannot be used.

    This also opens a new paradigm in bacterial infection treatment, as Alphanosos’ artificial intelligence based discovery method allows for the fast development of virtually unlimited number of new anti-bacterial treatments with a safety profile potentially acceptable for direct use in human.

    March 2016: Alphanosos secures total financing of € 2,603,750 well above objective of €1,500,000

    After having obtained during 2015/16 an amount of equity investments from private shareholders of € 1,210,250 and € 473,500 (non-interest bearing loan and grants) from the Auvergne General Council, Alphanosos received, in March 2016, an amount of € 920,000 (loan and non-interest bearing advance) from BPI France.

    Accordingly, Alphanosos secured during less than one year of activity a total financing of € 2,603,750 well above the initial objective of € 1,500,000.

    +33 982 216 506
    Alphanosos S.A.S.
    20-22 rue Henri et Gilberte Goudier,
    63200 Riom, France